Jul-23-20 Upgrade
Needham
Hold → Buy
Dec-11-19 Downgrade
Needham
Buy → Hold
Nov-01-19 Downgrade
Lake Street
Buy → Hold
$75 → $50
Aug-01-19 Reiterated
Needham
Buy
$65 → $68
May-02-19 Reiterated
Needham
Buy
$74 → $65
May-02-19 Reiterated
Lake Street
Buy
$90 → $75
Feb-21-19 Reiterated
Needham
Buy
$69 → $74
May-16-18 Reiterated
Needham
Buy
$46 → $55
Mar-01-18 Upgrade
Sidoti
Neutral → Buy
Feb-28-18 Reiterated
Lake Street
Buy
$35 → $38
Feb-28-18 Initiated
Needham
Buy
$42
Jul-14-17 Initiated
Lake Street
Buy
$40
Nov-21-16 Downgrade
Barrington Research
Outperform → Mkt Perform
Oct-06-16 Downgrade
Sidoti
Buy → Neutral
May-03-16 Reiterated
Barrington Research
Outperform
$27 → $30
Aug-06-15 Reiterated
Barrington Research
Outperform
$28 → $29
Mar-27-15 Initiated
Dougherty & Company
Buy
$33
Feb-25-14 Initiated
Laidlaw
Buy
$30
Aug-01-13 Upgrade
Feltl & Co.
Buy → Strong Buy
$31.25
Nov-12-12 Reiterated
Barrington Research
Outperform
$20 → $22
Apr-20-21 08:30AM
Apr-12-21 12:33PM
12:16PM
Apr-07-21 11:40AM
Apr-06-21 01:07PM
11:31AM
Apr-01-21 08:42AM
08:30AM
Mar-31-21 12:26PM
Mar-30-21 12:19PM
Mar-23-21 07:30PM
Mar-17-21 04:05PM
Mar-16-21 12:20PM
Feb-10-21 11:31AM
Feb-09-21 04:00PM
08:45AM
07:44AM
07:30AM
Feb-05-21 08:12AM
Feb-04-21 08:30AM
Feb-02-21 12:31PM
Feb-01-21 08:30AM
Jan-25-21 08:25AM
Jan-20-21 11:40AM
Jan-12-21 08:05AM
Dec-16-20 10:28AM
Dec-04-20 11:31AM
Nov-09-20 08:05AM
Nov-05-20 09:13AM
Nov-04-20 06:05PM
04:33PM
04:05PM
Oct-28-20 12:32PM
Oct-27-20 08:30AM
Oct-22-20 12:33PM
Oct-12-20 11:40AM
Sep-29-20 09:06AM
Sep-23-20 08:30AM
Sep-15-20 08:20AM
Sep-04-20 11:31AM
Aug-10-20 08:17AM
Aug-07-20 11:39AM
Aug-05-20 06:15PM
04:05PM
04:05PM
Jul-29-20 12:33PM
Jul-28-20 08:30AM
Jul-22-20 12:32PM
Jul-14-20 11:40AM
Jul-08-20 08:39AM
07:46AM
Jul-05-20 05:45PM
Jul-01-20 08:49AM
Jun-30-20 06:57AM
Jun-29-20 10:12AM
08:40AM
08:30AM
08:20AM
Jun-26-20 09:09AM
Jun-25-20 07:53AM
Jun-23-20 09:24AM
Jun-17-20 06:28AM
Jun-16-20 08:45AM
Jun-12-20 12:20PM
Jun-10-20 09:50AM
Jun-09-20 08:02AM
Jun-08-20 08:30AM
Jun-03-20 10:07AM
Jun-02-20 11:11AM
10:24AM
Jun-01-20 09:59AM
May-29-20 11:31AM
09:18AM
May-28-20 09:43AM
May-27-20 10:03AM
May-26-20 10:02AM
08:51AM
May-20-20 07:43AM
May-19-20 10:47AM
08:58AM
May-18-20 11:55AM
11:13AM
May-14-20 08:30AM
May-01-20 10:31AM
Apr-30-20 09:24PM Thomson Reuters StreetEvents
10:49AM
Apr-29-20 07:05PM
04:05PM
Apr-27-20 08:28AM
Apr-22-20 12:31PM
Apr-21-20 02:10PM
08:30AM
Apr-20-20 08:27AM
Apr-15-20 08:26AM
Apr-09-20 09:35AM
Apr-02-20 07:11AM
Mar-21-20 10:54AM
Mar-06-20 11:30AM
Feb-20-20 09:54AM
Feb-10-20 06:29PM Thomson Reuters StreetEvents
Surmodics, Inc., together with its subsidiaries, provides surface modification technologies for intravascular medical devices, and chemical components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. The company operates through two segments, Medical Device and In Vitro Diagnostics. The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for coronary, peripheral, neuro-vascular and structural heart, and other markets, as well as design, development, and manufacturing of interventional medical devices, primarily balloons and catheters, including drug-coated balloons for peripheral arterial disease treatment and other applications. The Vitro Diagnostics segment designs, develops, and manufactures component products and technologies for diagnostic immunoassay, as well as molecular test and biomedical research applications. This segment offers protein stabilization reagents, substrates, surface coatings, and antigens. Surmodics, Inc. was founded in 1979 and is headquartered in Eden Prairie, Minnesota.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
OLSON CHARLES W Senior VP of Bus Dev, Med Dev Apr 16 Sale 59.75 648 38,718 42,092 Apr 20 04:15 PM OLSON CHARLES W Senior VP of Bus Dev, Med Dev Mar 31 Sale 56.75 4,759 270,073 42,740 Apr 02 02:30 PM Maharaj Gary R President & CEO Mar 01 Sale 52.06 4,000 208,259 164,713 Mar 03 06:12 PM KNIGHT SUSAN E Director Feb 26 Option Exercise 21.31 5,576 118,825 34,290 Mar 02 04:06 PM OLSON CHARLES W Senior VP of Bus Dev, Med Dev Feb 26 Option Exercise 20.46 13,533 276,827 56,638 Mar 02 04:07 PM KNIGHT SUSAN E Director Feb 26 Sale 52.36 5,576 291,955 28,714 Mar 02 04:06 PM Arens Timothy J. Chief Financial Officer Feb 24 Option Exercise 20.44 10,973 224,242 65,076 Feb 26 04:02 PM BEDOYA JOSE H Director Feb 23 Sale 50.68 1,497 75,868 22,817 Feb 25 04:33 PM Stich Joseph J. SVP, HR and GM, IVD Feb 16 Sale 51.69 2,500 129,237 48,062 Feb 18 04:37 PM KALICH RONALD B SR Director Feb 12 Option Exercise 26.46 4,098 108,433 23,504 Feb 16 04:50 PM Maharaj Gary R President & CEO Feb 11 Option Exercise 22.36 82,264 1,839,571 224,406 Feb 16 04:52 PM Maharaj Gary R President & CEO Feb 01 Sale 44.81 3,000 134,423 142,142 Feb 03 04:14 PM Stich Joseph J. SVP, HR and GM, IVD Jan 05 Sale 45.00 2,500 112,500 50,562 Jan 07 04:37 PM Maharaj Gary R President & CEO Jan 04 Sale 43.96 2,000 87,926 145,142 Jan 06 04:25 PM BEDOYA JOSE H Director Nov 17 Option Exercise 22.58 3,575 80,724 25,325 Nov 19 05:06 PM DANTZKER DAVID Director Nov 10 Option Exercise 22.58 3,575 80,724 30,471 Nov 13 04:20 PM Maharaj Gary R President & CEO Sep 01 Sale 45.07 3,000 135,206 135,399 Sep 03 05:06 PM Stich Joseph J. SVP, HR and GM, IVD Aug 19 Sale 46.71 2,500 116,781 51,570 Aug 21 03:20 PM Maharaj Gary R President & CEO Aug 03 Sale 47.44 3,000 142,334 138,142 Aug 05 04:28 PM Stich Joseph J. SVP, HR and GM, IVD Jul 22 Option Exercise 22.58 12,612 284,779 63,488 Jul 24 05:24 PM Maharaj Gary R President & CEO Jul 01 Sale 43.02 2,000 86,037 141,142 Jul 06 06:10 PM Stich Joseph J. SVP, HR and GM, IVD Jun 09 Sale 45.00 2,500 112,500 51,499 Jun 11 05:47 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite